Targeted Therapy with Biologicals and Small Molecules in Primary Immunodeficiencies.
Primary immunodeficiencies (PIDs) are disorders resulting from mutations in genes involved in immune host defense and immunoregulation. These conditions are characterized by various combinations of recurrent infections, autoimmunity, lymphoproliferation, inflammatory manifestations, and malignancy. In the last 20 years Newborn screening (NBS) programs and Next Generation Sequencing (NGS) techniques, have increased the ability to diagnose PID. Furthermore the advanced understanding of the molecular basis of these inherited disorders led to the implementation of targeted therapies that utilize small molecules and biologics to modulate the activity of impaired intracellular pathway. This article will discuss selected PID, whose genetic defects have been recently studied and are amenable to targeted therapy as a reflection of the potential of precision medicine in the future.